Skip to main content
Selank Source

A scholarly research digest on Selank — the tuftsin-analog anxiolytic heptapeptide, its GABAergic, enkephalinase, BDNF and monoamine signals, and an honest map of where the evidence is single-region and thin.

Selank papers · who was tested

Selank references show where each claim came from

Use the paper links to check whether a test involved people, animals, blood, or brain tissue.

Return to the study guideRead the effects and risks

Each paper helps you judge one Selank claim

A bracketed number beside a claim points to a paper. The link opens a public record or journal page when one is available. You can then check who or what was tested. Start there when a claim sounds too sure.

Many papers came from Russian teams and Russian-language journals. Some offer only a short English summary. Some have no direct journal link. Those limits make the human claims less sure.

A paper listing isn't a mark of approval. It tells you where the claim came from. First ask whether the test used people, animals, blood, or cells. Then ask what changed and whether the change helped.

Selank papers cover people, animals, and blood tests

The Selank papers cover anxiety, memory, brain changes, blood tests, and safety. Each [N] mark on another page points to one paper. A patient study carries more weight for you than an animal test. Even a patient study can be too small or short to settle a claim.

Selank papers cover people, animals, and blood tests

Cited sources

  1. Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and Peptide Letters. 2018;25(10):914-923. ↗
  2. Zozulya AA, Kost NV, Sokolov OYu, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of Experimental Biology and Medicine. 2001;131(4):315-317. ↗
  3. Inozemtseva LS, Karpenko EA, Dolotov OV, et al. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Doklady Biological Sciences. 2008;421:241-243. ↗
  4. Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology. 2016;7:31. ↗
  5. Uchakina ON, Uchakin PN, Miasoedov NF, et al. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2008;108(5):71-75. ↗
  6. Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic medication (selank) in the therapy of generalized anxiety disorders and neurasthenia. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2008;108(4):38-48. ↗
  7. Kasian A, Kolomin T, Andreeva L, et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behavioural Neurology. 2017;2017:5091027. ↗
  8. Semenova TP, Kozlovskaya MM, Zuikov AV, et al. Use of Selank to correct measures of integrative brain activity and the level of biogenic amines. Neuroscience and Behavioral Physiology. 2008;38(2):203-207. ↗
  9. Narkevich VB, Kudrin VS, Klodt PM, et al. Effects of heptapeptide selank on the content of monoamines and their metabolites in the brain of BALB/c and C57Bl/6 mice. Eksperimental'naia i Klinicheskaia Farmakologiia. 2008;71(5):8-12. ↗
  10. Semenova TP, Kozlovskii II, Zakharova NM, et al. Comparison of the effects of selank and tuftsin on the metabolism of serotonin in the brain of rats. Eksperimental'naia i Klinicheskaia Farmakologiia. 2009;72(4):6-8. ↗
  11. Slominsky PA, Shadrina MI, Kolomin TA, et al. Peptides Semax and Selank Affect the Behavior of Rats with 6-OHDA Induced Parkinsonism. Doklady Biological Sciences. 2017;474(1):106-109. ↗
  12. Vasil'eva EV, Kondrakhin EA, Salimov RM, et al. Comparison of Pharmacological Effects of Heptapeptide Selank After Intranasal and Intraperitoneal Administration. Eksperimental'naia i Klinicheskaia Farmakologiia. 2016;79(9):3-11. ↗
  13. Kozlovskii II, Belozertsev IuF, Semenova TP, et al. Compensatory effect of selank on the mnestic functions disturbed by neurotoxin MPTP in rats. Eksperimental'naia i Klinicheskaia Farmakologiia. 2008;71(2):3-7. ↗
  14. Kozlovskii II, Belozertsev FIu, Andreeva LA, et al. Protective effect of selank on the model of mnestic function violation induced by MPTP in rats. Eksperimental'naia i Klinicheskaia Farmakologiia. 2013;76(12):3-7. ↗
  15. Pavlov TS, Sanzhieva LTs, Samonina GE, et al. Effect of new synthetic anxiolytic selank on gastric wall blood flow and protective properties of gastric mucosa. Rossiiskii Fiziologicheskii Zhurnal imeni I.M. Sechenova. 2005;91(2):178-183. ↗
  16. Medvedev VE, Tereshchenko ON, Kost NV, et al. Optimization of the treatment of anxiety disorders with selank. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2015;115(6):33-40. ↗
  17. Fomenko EV, Bobyntsev II, Kryukov AA, et al. Effect of Selank on Functional State of Rat Hepatocytes under Conditions of Immobilization Stress. Bulletin of Experimental Biology and Medicine. 2017;163(4):415-418. ↗
  18. Leonidovna YA, Aleksandrovna SM, Aleksandrovna TA, et al. The Influence of Selank on the Level of Cytokines Under the Conditions of Stressogenic Effect. Current Reviews in Clinical and Experimental Pharmacology. 2021;16(2):162-167. ↗
  19. Ershov FI, Uchakin PN, Uchakina ON, et al. Antiviral activity of immunomodulator Selank in experimental influenza infection. Voprosy Virusologii. 2009;54(5):19-24. ↗